About this trial
Coronary artery bypass graft (CABG) surgery is still the standard treatment of coronary revascularization for patients with severe coronary artery disease (CAD). Graft patency, together with completeness of revascularization, is a major determinant of long-term outcome following CABG. The surgical procedure elicits a persistent systemic inflammatory response associated with the activation of the hemostatic system leading to perturbation of endothelial and vascular function and activation of platelets and leukocytes. All of these events are the main players responsible for the early and late graft failure in a significant percentage of patients.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
between the ages of 40 and 80
Ejection fraction> 30%
coronary artery bypass surgery
informed consent
Disqualifiers
emergency intervention
changes in liver or kidney function
changes in coagulation factors
associated interventions (valve replacement, carotid endarterectomy)
Trial population
patients undergoing elective CABG ( coronary artery bypass graft )
Trial design
Case-only
Prospective
Treatments tested in this trial
Not listed
Trial groups
Trial outcomes
Primary outcomes
Confirmation and validation of the potential role of blood MV and exosomes as predictors of bypass occlusions
Sponsors and contacts
Click on the lead sponsor to view all of their trials.